“COVID-19 may have put the pharma industry on the fast track to doing things differently – an industry that for the most part embraces change rather slowly. Will this novel virus be the catalyst for change in how traditional clinical trials are conducted? Can the strict protocol be more lenient? Can the standardized methods have some exceptions?”Read the full article at Bioprocess Online, and check out our Trends & Technology reports for more trends based on responses from industry experts.
Market Research Director at Industry Standard Research Sherry Hubbard-Bednasz identifies trends taking place in the clinical development industry that indicate a shift to more flexibility during clinical research, especially in light of the COVID-19 crisis.